{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:41:38Z","timestamp":1757612498342,"version":"3.44.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In presensitized kidney transplantation with positive donor-specific antibody (DSA), the activation of immune memory responses leads to a significant increase in DSA levels, followed by early active antibody-mediated rejection (early aAMR). For some patients, it is difficult to eliminate DSA and reverse aAMR after conventional treatments such as plasmapheresis (PP) and intravenous immunoglobulin (IVIG). Here we report three cases of successful reversal of refractory early aAMR after DSA-positive presensitized kidney transplantation by using adjuvant splenic irradiation therapy. At 1 to 2 weeks after kidney transplantation, all three of our recipients experienced a significant increase in DSA levels, accompanied by deterioration of renal allograft function. The aAMR of two patients was diagnosed by renal biopsy, and the other was diagnosed clinically. After 5 to 11 sessions of PP\/IVIG treatment, the DSA levels of all three patients failed to decrease, or even continued to rise. Therefore, in addition to PP\/IVIG treatment, all three patients received 10 sessions of low-dose repetitive splenic irradiation (50cGy per session) as adjuvant therapy. As a result, the levels of all DSAs began a continuous decline, and renal function gradually returned to normal or approached normal. Eventually, all three patients recovered and were discharged from the hospital. During the 14- to 75-month follow-up period, the DSA of two patients became negative, while that of the remaining one patient remained at a low level. Renal function was stable during the follow-up period. Thus, when early aAMR that resists conventional treatment occurs after presensitized kidney transplantation, splenic irradiation may be an important adjuvant treatment option.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1670507","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:52:30Z","timestamp":1756990350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Adjuvant splenic irradiation therapy effectively eliminates donor-specific antibodies and reverses refractory early active antibody-mediated rejection after presensitized kidney transplantation"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhiliang","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rula","family":"Sa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuheng","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002691","article-title":"Clinical relevance of posttransplant dsas in patients receiving desensitization for hla-incompatible kidney transplantation","volume":"103","author":"Vo","year":"2019","journal-title":"Transplantation"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01686.x","article-title":"Determinants of poor graft outcome in patients with antibody-mediated acute rejection","volume":"7","author":"Lefaucheur","year":"2007","journal-title":"Am J Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001650","article-title":"Long-term outcomes of kidney transplantation in patients with high levels of preformed dsa: the necker high-risk transplant program","volume":"101","author":"Amrouche","year":"2017","journal-title":"Transplantation"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the transplantion society working group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1223567","article-title":"A modified perioperative regimen for deceased donor kidney transplantation in presensitized recipients without prior desensitization therapy","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf097","article-title":"Antibody-mediated rejection-treatment standard","volume":"40","author":"Bohmig","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: ritux erah, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2017.01.002","article-title":"A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection","volume":"31","author":"Macklin","year":"2017","journal-title":"Transplant Rev (Orlando)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15922","article-title":"Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab","volume":"20","author":"Jordan","year":"2020","journal-title":"Am J Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182a72115","article-title":"Down-regulating humoral immune responses: implications for organ transplantation","volume":"97","author":"Stegall","year":"2014","journal-title":"Transplantation"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.390","article-title":"Restricted specificity of peripheral alloreactive memory B cells in hla-sensitized patients awaiting a kidney transplant","volume":"87","author":"Snanoudj","year":"2015","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04009.x","article-title":"The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients","volume":"12","author":"Sicard","year":"2012","journal-title":"Am J Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13882","article-title":"Splenic irradiation for the treatment of severe antibody-mediated rejection","volume":"16","author":"Orandi","year":"2016","journal-title":"Am J Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661614","article-title":"Case report: splenic irradiation for the treatment of chronic active antibody-mediated rejection in kidney allograft recipients with de novo donor-specific antibodies","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002049","article-title":"The treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis","volume":"102","author":"Wan","year":"2018","journal-title":"Transplantation"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000001011","article-title":"Antibody-mediated rejection: prevention, monitoring and treatment dilemmas","volume":"27","author":"Rodriguez-Ramirez","year":"2022","journal-title":"Curr Opin Organ Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/s0140-6736(10)61493-6","article-title":"Post-splenectomy and hyposplenic states","volume":"378","author":"Di Sabatino","year":"2011","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01709.x","article-title":"The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection","volume":"7","author":"Locke","year":"2007","journal-title":"Am J Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2011.01518.x","article-title":"Successful rescue of refractory acute antibody-mediated renal allograft rejection with splenectomy\u2013a case report","volume":"16","author":"Roberti","year":"2012","journal-title":"Pediatr Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.07.044","article-title":"Evaluation of severe infection and survival after splenectomy","volume":"119","author":"Kyaw","year":"2006","journal-title":"Am J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.3390\/cells10113251","article-title":"Dose and dose rate-dependent effects of low-dose irradiation on inflammatory parameters in apoe-deficient and wild type mice","volume":"10","author":"Glasow","year":"2021","journal-title":"Cells"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-8140(00)00316-9","article-title":"Clinical indications and biological mechanisms of splenic irradiation in chronic leukaemias and myeloproliferative disorders","volume":"58","author":"Weinmann","year":"2001","journal-title":"Radiother Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/imr.13016","article-title":"Memory B cells and plasma cells: the differentiative continuum of humoral immunity","volume":"303","author":"Cancro","year":"2021","journal-title":"Immunol Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1670507\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:52:32Z","timestamp":1756990352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1670507\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2025.1670507"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1670507","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1670507"}}